20 February 2025
In recent decades, there has been an increase in the range of biologics and synthetic DMARDs for the treatment of various subtypes of Juvenile Idiopathic Arthritis (JIA).
While this has expanded therapeutic options, access to these treatments varies between paediatric, adolescent, and adult services, as well as across the four nations of the UK.
The UK Juvenile Idiopathic Arthritis (JIA) Topic Specific Group has developed a survey to examine both on-label and off-label use of biologics and targeted synthetic DMARDs in JIA treatment across different regions and age groups.
The survey is designed to be completed by an MDT rather than individuals and the results from this survey will help them understand differences in care, health inequity, as well as informing the planned update of the NHS England JIA Biologic Treatment Pathway from 2015.
If you look after patients, of any age, who have had a diagnosis of JIA, the UK JIA Topic Specific Group would very much appreciate your views.
The survey can be accessed here and the deadline for responses is 15 April 2025.
If your NHS Trust restricts access to Google Docs, you can complete the survey using the PDF version with your MDT. Then, a member of your MDT can enter the responses using a device that has access to Google Forms.